Lifeboat Foundation

The U.S. Food and Drug Administration (FDA) approved the first blood test that looks for the antibodies against the novel coronavirus that causes COVID-19. This is different than assays that test for presence of the virus—those test to determine if a patient has COVID-19. These new antibody tests determine if the person was exposed to the virus, had COVID-19 and recovered. And it suggests, if positive, that the person is now immune to COVID-19 and can’t get it again.

Research Triangle Park, North Carolina-based Cellex was granted an emergency use authorization (EUA) on its test yesterday.

The test is performed on a blood sample taken from a patient’s vein and can be performed by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), the Health and Human Services division that oversees clinical diagnostic testing in the United States.

HOUSTON — A University of Houston professor is waiting for FDA approval of a waterproofing solution that he says can shield personal protective equipment such as N95 masks from the droplets that spread COVID-19.

Professor Seamus Curran said he developed the hydrophobic coating in 2011 while testing it on fabrics. He continued creating similar solutions to be used on wood and masonry with his company, Integricote.

When COVID-19 broke out, he felt the coating could help, especially as health care workers warned of a nationwide shortage of personal protective equipment (PPE) such as N95 masks that health care workers wear.

IBM quantum computer runs machine-learning algorithm to find Higgs events.

Coronavirus is sending in the drones. In what’s being billed as a “world first,” startup Manna Aero has begun a drone delivery service in Moneygall, Ireland. Delivering medicine to vulnerable people locked in their homes, it provides yet another strong example of how technology is helping the world adjust to life in the shadow of the coronavirus.

Having received authorisation from the Irish Aviation Authority, Manna Aero’s service began last Friday as a pilot in Moneygall, which was previously best known as Barack Obama’s ancestral village. However, if the trial is successful, the service will be rolled out throughout Ireland, and could also be used to deliver food.

The drones will deliver prescription orders for medicine to around a dozen households. As Manna Zero’s founder Bobby Healy told the Irish Independent, the drones ensure “zero human-contact” and can execute deliveries “in ways normal delivery can’t.”

Shortly after the failure, SpaceX’s founder and chief engineer, Elon Musk, said on Twitter, “We will see what data review says in the morning, but this may have been a test configuration mistake.” A testing issue would be good in the sense that it means the vehicle itself performed well, and the problem can be more easily addressed.

This is the third time a Starship has failed during these proof tests that precede engine tests and, potentially flight tests. Multiple sources indicated that had these preliminary tests succeeded, SN3 would have attempted a 150-meter flight test as early as next Tuesday.

Continue reading “SpaceX loses its third Starship prototype during a cryogenic test” »

Researchers at UCSF have trained an algorithm to parse meaning from neural activity.

One week ago…

“Gasoline in the United States has fallen to about $2 a gallon and continues to slide. However, that price is nowhere near the least expensive in the world. Venezuela has the least expensive gas in the world at two cents per gallon.”

There is an ongoing battle between cancer cells and p53, the protein known as “the guardian of the genome,” and a study conducted at the University of Trento has identified a number of factors that influence the outcome of this battle and therefore the effectiveness of cancer treatments.

Scientists explore two therapeutic cancer treatment scenarios: In one scenario, cancer cells stop proliferating; in the other, their death rate increases. Both of these outcomes are regulated the protein p53. Based on the new findings, a specific factor, a protein known as DHX30, determines how p53 can lead cancer cells to their death. That is the conclusion reached by a team of researchers of the University of Trento, who focused on a new molecular mechanism that works like a switch.

Erik Dassi, member of the research team, said, “When cancer cells are treated with a certain drug, it is the action of this switch (DHX30) that makes them to go toward cell death and not in the direction of cell cycle arrest.”